Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature

Tamoxifen is a selective oestrogen receptor modulator (SERM) with anti-oestrogenic activity in the breast and oestrogenic effects in various tissues such as the endometrium, bone and cardiovascular territory. As adjuvant hormone therapy, it has a clear beneficial effect in patients with breast cancer, reducing relapses, contralateral breast cancer and mortality. Its most important secondary effect is a greater rate of occurrence of endometrial cancer. Although the risk/benefit ratio is clearly positive, the follow-up on these patients is still an issue. In women with metrorrhagia, it is clear that an endometrial sample must be obtained for histological examination and the best procedure today is hysteroscopic-directed biopsy. Nevertheless, the need to screen asymptomatic patients is not universally accepted. The vaginal ultrasound scan gives a great number of false positives. This entails more aggressive and more expensive procedures such as hysteroscopic-directed biopsy, meaning greater expense and more complications. As a result, the cost/benefit ratio is not very favourable. The rate of occurrence of endometrial cancer in 1026 tamoxifen-treated patients with breast cancer in our hospital between 1999 and 2001 was 1.25%. Two cases were diagnosed in asymptomatic patients. In this article, we analyse the literature on the need to screen patients on tamoxifen and about the most appropriate diagnostic protocol.

Tamoxifen; Endometrial cancer; Endometrial effects; Screening

[1] Beatson G.T.: "On the treatment of inoperable cases of the mamma: suggestions for new method of treatment with illustrative cases". Lancet, 1986, 2, 104.

[2] Schizinger A.: "Uber carcinoma mammae". Verh. Dtsch Ges. Chir, 1889, 18, 28.

[3] Cole M.P., Jones C.T.A., Todd l.D.H.: "A new antiestrogenic agent in late breast cancer: An early clinical appraisal of ICI 46,474". Br. J. Cancer, 1971, 25, 270.

[4] Neven P., Vernaeve H.: "Guidelines for monitoring patients taking tamoxifen treatment". Drug. Safety, 2000, 22.

[5] Powles T.J.: "Efficacy of Tamoxifen as treatment of breast cancer". Semin. Oneal., 1997, 24 (suppl. 1), 48.

[6] Forbes J.P.: "The control of breast cancer: the role of tamoxifen". Semin. Oncol., 1997, 24 (suppl. I), 5.

[7] Fisher B., Constantino J.P., Wickerman D.L., Redmon C.K., Kavanah M., Cronin W.M. et al.: "Tamoxifen for the preventionof breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study". J. Natl. Cancer Inst., 1998, 90, 1371.

[8] Ault A.: "Tamoxifen prevention claim will not be allowed in the USA". Lancet, 1998, 352, 883.

[9] Speroff L., Glass R.H., Kase G.K.: "Biosfntesis, metabolismo y mecanismo de acci6n de las hormonas (capt. 2)". Endocrinologia Ginecol6gica e Infertilidad (I" edition in Spanish).

[10] Sutherland R.L., Green M.D., Hall R.E., Reddel R.R., Taylor l.W: "Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in GO/GI phase of the cell cycle". Eur. J. Clin. Oneal., 1983, 19, 615.

[11] Gustall J.P., Catimel G., Blay J.Y. et al.: "Tratamiento del cancer de mama no metastatico: formas hahituales". Enciclopedia Medico-Quirurgica, 871-A-10.

[12] Murphy L.C.: "Antiestrogen action and growth factor regulation". Breast Cancer Res. Treat., 1994, 31, 61.

[13] Neven P., Vergote I.: "Tamoxifen, screening and new oestrogen receptor modulators". Best Prac. Res. Clin. Obstet. Gynaecol., 2001, 15, 365.

[14] Fisher B., Dignam J., Bryan J. et al.: "Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumours". J. Natl. Cancer Inst., 1996, 88, 1529.

[15] Sterwart H.J., Forrest A.P., Everington D. et al.: "Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer". Br. J Cancer, 1996, 74, 297.

[16] Horwitz K.B.: "Hormone-resistant breast cancer or'feeding the hand that bites you'". Prag. Clin. Biol. Res., 1994, 387, 29.

[17] Killackey M.A., Hakes T.B., Pierce V.K.: "Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens". Cancer Treat. Rep., 1985, 69, 237.

[18] Rutqvist L.E., Johanson H., Signomklao T., Johansson U., Fornander T., Wilking N.: "Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies". J. Natl. Cancer Inst., 1995, 87, 645.

[19] Fisher B., Constantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M.: "Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14". J. Natl. Cancer Inst., 1994, 86, 527.

[20] Curtis R.E., Boice J.D., Shriner D.A., Hnakey B.F., Fraumeni J.P.: "Second cancers after adjuvant therapy for breast cancer". J. Natl. Cancer Inst., 1996, 88, 332.

[21] Early Breast Cancer Trialists'Collaborative Group: "Tamoxifeno para el cancer de mama precoz. En: La Cochrane Library plus en espafiol Oxford: Update Software".

[22] Speroff L., Glass R.H., Kase G.K.: "Las mamas (capt. 16)". Endocrinologia Ginecol6gica e lnfertilidad (I" edition in Spanish).

[23] Mourits M.J.E., De V ries E., Willense P., Ten Hoor K., Hollema H., Van der Zee A.:'Tamoxifen treatment and gynecologic side effects: A review". Obstet. Gynaecol., 2001, 97, 5.

[24] Berstein L., Deapen D., Cerhan J.R., Swartz S., Liff J., McGann-Maloney E., Pearlman J.A., Ford L.: "Tamoxifen therapy for breast cancer and endometrial cancer risk". J. Natl. Cancer Inst., 1999, 91, 1654.

[25] Powles T.J., Bourne T., Athanasious S. et al.: "The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy postmenopausal woman on tamoxifen or placebo". Br. J. Cancer, 1998, 78, 272.

[26] Gardner F.J.E., Konje J.C., Abrams K.R. et al.: "Endometrial protection from tamoxifen stimulated changes by a levonorgestrel releasmg intrauterine system: a randomized controlled trial". Lancet, 2000, 356, 1711.

[27] Magriples U., Boice J.D., Shriner D.A., Hankey B.F., Fraumeni J.P. et al.: "High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Clin. Oneal., 1993.

[28] Barakat R.R., Wong G., Curtin J.P. et al.: "Tamoxifen use in breast-cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features". Gynecol. Oneal., 1994, 55, 164.

[29] Bergman L., Beelen M.L.R., Gelmann E.P.: "Risk and prognosis of endometrial cancer after tamoxifen for breast cancer". Lancet, 2000, 356, 881.

[30] Wickerham D.L., Fisher B., Wolmark N. et al.: "Association of tamoxifen and uterine sarcoma". J. Clin Oneal., 2002, 20, 2758.

[31] O'Regan R., Craig J.: "Tamoxifen and raloxifene and beyond". Semin. Oneal., 2001, 28, 260.

[32] Neven P., De Muylder X., Van Belle Y., Van Hoof V., Vanderick G.: "Longintudinal hysteroscopic follow-up during tamoxifen treatment" Lancet, 1998, 351, 36.

[33] Ascher S.M., Imakoa I., Lage J.M.:'Tamoxifen-induced uterine abnormalities: The role of imaging". Radiology, 2000, 214, 29.

[34] Ismail S.M.: "Pathology of endometrium treated with tamoxifen". J. Clin. Pathol., 1994, 47, 827.

[35] McGonigle K.F., Swaw S.L., Vasilev S.A., Odom-Maryon T., Roy S., Simpson J.P.: "Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy". Am. J. Obstet. Gynecol.. 1998, 178, 1145.

[36] Goldstein S.R.: "Unusual ultrasonic appearance of the uterus in patients receiving tarnoxifen". Am. J. Obstet. Gynecol.,1994, 170, 447.

[37] Vosse M., Renard F., Coibion M., Neven P., Nogaret J.M., Hertens D.: "Endornetrial disorders in 406 breast cancer patients on tarnoxifen: the case for less intensive monitoring". Eur. J. Obstet. Gynecol. Rep rod. Biol., 2002, 101, 58.

[38] Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E.: "Tamoxifen and the uterus and endometriurn". Lancet, 1989, 2, 375.

[39] Lahti E., Blanco G., Kauppila A., Apaja-Sarkiknen M., Taskinen P.J., Laatiniken T.: "Endornetrial changes in postrnenopausal breast cancer patients receiving tamoxifen". Obstet. Gynecol., 1993, 81, 660.

[40] Cohen I.,A zaria R.,B erheim J., Enhapira J.,B eyth T.: "Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen". Cancer, 2001, 92, 1151.

[41] Biron-Shental T., Tepper R., Fishman A., Shapira J., Cohen I.: "Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen". Gynecol. Oncol., 2003, 90, 382.

[42] Cohen I.,B ernheim J.,A zaria R.,T epper R.,S harony R.,B eyth Y.: "Malignant endometrial polyps in postmenopausal breast cancer tamoxifentreated patients". Gynecol. Oncol., 1999, 75, 136.

[43] McCluggage W.G., Sumathi M., McManus M.: "Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endornetrial polyps, report of 5 cases, including 2 associated with tamoxifen therapy". Hum. Pathol., 2003, 34, 939.

[44] Berliere M., Galant C., Donnez J.: "The potential oncogenic effect of tamoxifen on the endometrium". Human Reprod.,1999, 14, 1381.

[45] Varras M.,P olyzos D.,A krivis Ch.: "Effects of tamoxifen on the female's genital tract: review of the literature". Eur. J. Gynaecol. Oncol., 2003, 24, 3.

[46] Kedar R.P., Bourne T.H., Powles T.J. et al.: "Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial". Lancet, 1994, 343, 1318.

[47] Klopper A., Hall M.: "New synthetic agent for the induction of ovulation. Preliminary trial in women". Br. J. Med., 1971, 2, 152.

[48] Kazandi M., Sendag F., Terk M., Ozsaran A., Dikmen Y.: Eur. J. Gynaecol. Oneal., 2002, 23, 257.

[49] Chang J., Powles T.J., Ashley S.E., Iveson T., Gregory R.K., Dowsett M.: "Variation in endometrial thickening in women with amenorrhea on tamoxifen". Breast Cancer Res. Treat., 1998, 48, 81.

[50] Love R.R.,N ewcomb P.A. et al.: "Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer". J. Natl. Cancer Inst., 1990, 82, 3191.

[51] Elisaf M.S.,N akou K.,L iamis G.,P aulidis N.A.: "Tamoxifen-induced severe hypertriglyceridemia and pancreatitis". Ann. Oncol., 2000, 11, 1067.

[52] Love R.R., Mazes R.B., Barden H.S. et al.: "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer". N Engl. J. Med., 1992, 326, 852.

[53] Lazzaroni F., Scorolli L. et al.: "Tamoxifen retinopathy: does it really exist?". Graesfes Arch. Clin. Exp. Opththalmol., 1998, 236, 669.

[54] Brown K.: "Breast cancer chemoprevention: risk-benefit effects of the anti-oestrogen tamoxifen". Expert. Opin. Drug Sqf., 2002, 1, 253.

[55] Braithwaite R.S., Rowan T. et al.: "Meta-analysis of vascular and neoplasic events associated with tamoxifen". J. Gen. Intern. Med., 2003, 18, 937.

[56] Mourits M.J.E., Van der Zee A.G.J. et al.: "Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen". Gynecol. Oncol., 1999, 73, 21.

[57] Rayter Z., Watt M., Keay S. et al.: "The effect of tamoxifen on endometrial thickness and endometrial histology". Eur. J. Cancer, 2000, 36, S98.

[58] McGonigle K.F., Marx H.F., Morgan R.J. et al.: "Uterine effects of tamoxifen: a prospective study". Gynecol. Oncol., 1999, 74, 324.

[59] Love C.D.B., Dixon J.M.: "Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation". The Breast, 2000, 9, 156.

[60] Gerber B., Krause A., Millier H. et al.: "Effects of adjuvant tamoxifen on the endometriurn in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound". J. Clin. Oncol., 2000, 18, 3464.

[61] Love C.D.P., Muir B.B. et al.: "Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening". J. Clin. Oncol., 1999, 17, 2050.

[62] Ciatto S., Cechini S., Gervasi G., Landini A., Zappa M., Crocetti E.: "Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment". Br. J. Cancer, 2003, 88, 1178.

[63] Renard F., Vosse M., Scagnol I., Verhest A.: "Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. Case report". Eur. J. Gynaecol. Oneal., 2002, 23

[64] Seoud M., Shamseddine A., Khalil A. et al.: "Tamoxifen and endometrial pathologies: A prospective study". Gynecol. Oncol., 1999, 75, 15.

[65] Love R.R.: "Tamoxifen prophylaxis in breast cancer". Oncol., 1992, 6, 33.

[66] Fung K., Fung M., Reid A. et al.: "Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tarnoxifen". Gynecol. Oneal., 2003, 91, 154.

[67] Bourne T.H.,L awton F.,L eather A., Grandberg S.,C ambell S.,C ollins W.P.: "Use of intracavitary saline instillations and transvaginal sonography to detect tamoxifen associated endometrial polyps". Ultrasound Obstet. Gynecol., 1994, 4, 73.

[68] F ong K., Causer P. et al.: "Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifeno: Correlation with hysteroscopy and pathology study". Radiographics, 2003, 23, 137.

[69] Tepper R., Beyth Y., Altaras M.M. et al.: "Value of sonohysterography in asymptomatic post menopausal tamoxifen-treated patients". Gynecol Oncol., 1997, 64, 386.

[70] Hann L., Cathleen M., Gonen M., Barakat R., Choi P., Bach A.: "Sonohysterography compared with endometrial biopsy for evaluation of the endornetrium in tamoxifen-treated women". J. Ultrasound Med., 2003, 22, 1173.

[71] Garuti G., Sambruni I. et al.: "Accuracy of hysteroscopy in predicting histopathology of endometrium in 1500 women". J. Am. Assoc. Gynecol. Laparosc., 2001, 8, 207.

[72] Oronzo C., Betochi S. et al.: "Comparison of hysteroscopic and hysterectomy findings to asses the diagnostic accuracy of office hysteroscopy in tamoxifen-treated patients with breast cancer". J. Am. Assoc. Gynecol. Laparosc., 2003, 10, 392.

[73] Cohen I., Azaria R. et al.: "Comparison of endometrial pathologies collected by hysteroscopy and hysterectomy in postrnenopausal breast cancer tamoxifen-treated patients". Eur. J. Gynecol. Oncol., 2000, 21, 418.

[74] Taponecco F., Curcio C. et al.: "Indication of hysteroscopy in tamoxifen treated breast cancer patients". J. Exp. Clin. Cancer Res., 2002, 21, 1.

[75] Machado F., Moreno J. et al.: "Accuracy of endometrial biopsy with the Cornier pipelle for diagnosis of endometrial cancer and atypical hyperplasia". Eur. J. Gynaec. Oneal., 2003, 24, 279.

[76] Shu-Bergman E.J., Goodman A.: "Surveillance for endometrial cancer in women receiving tamoxifen". Ann. Intern. Med., 1999, 131, 127.

[77] Barakat R.R., Gilewski T.A. et al.: "Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy". J. Clin. Oncol., 2000, 18, 3459.

[78] Labi FL., Meggirione M.P. et al.: "Cytological endometrial surveillance in tamoxifen-treated women". Eur. J. Gynaecol. Oneal., 2002, 23, 537.

[79] Aleem F., Predanic M. et al.: "Trans vaginal color and pulsed Doppler sonography of the endometrium: a possible role in reducing the number of dilatation and curettage procedures". J. Ultrasound Med., 1995, 14, 139.

[80] Achiron R., Lipitz S., Sivan E. et al.: "Changes mimicking endometrial neoplasia in tamoxifen-treated women with breast cancer: a transvaginal Doppler study". Ultrasound in Obstetric and Gynaecol., 1995, 6, 116.

[81] Alcazar J.L., Castillo G. et al.: "Endometrial blood flow mapping using trans vaginal power Doppler sonography in woman with postmenopausal bleeding and thickened endometrium". Ultrasound Obstet. Gynecol., 2003, 21, 583.

[82] Asher S.M., Johnson J.C., Zeman R.K., Patt R.H.: "Uterine changes in women receiving tamoxifen therapy: Prospective comparison of MRI and transvaginal sonography with pathologic correlation". Radiology, 1995, 197, 353.

[82] Goldstein S.R.: "Controversy about uterine effects and safety of SERMs: the saga continues". Menopause, 2002, 9, 381.

[83] Dallenbach-Hellweg G., Schmidt D. et al.: Arch. Gynecol. Obstet., 2000, 263, 170.

[84] Marttunen M.B., Cacciarote B. et al.: "Prospective study on gynaecological effects of two antiestrogens tamoxifen and toremifene in postmenopausal women". Brit. J. Cancer, 2001, 84, 897.

[85] Barakat R.R., Gilewski T. et al.: "The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study" Proc. Am. Soc. Clin. Oncol., 1999, 18, 358.

[86] Neven P., Vernaeve H.: Drug Safety, 2000, 22, 1.

[87] Guerrieri J.P.; Elkas J.C., Nash J.D.: "Evaluating the endometrium in women on tamoxifen: a pilot study to compare a'gold standard' with an 'old standard"'. Menopause, 1997, 4, 6.